(Q44805753)
Statements
A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer (English)
Filippo Montemurro
Gabriella Choa
Roberto Faggiuolo
Michela Donadio
Monica Minischetti
Antonio Capaldi
Guido Vietti-Ramus
Oscar Alabiso
1 January 2004